Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
(2017) In Cancer Immunology and Immunotherapy 66(1). p.1-7- Abstract
The most important goals for the field of immuno-oncology are to improve the response rate and increase the number of tumor indications that respond to immunotherapy, without increasing adverse side effects. One approach to achieve these goals is to use tumor-directed immunotherapy, i.e., to focus the immune activation to the most relevant part of the immune system. This may improve anti-tumor efficacy as well as reduce immune-related adverse events. Tumor-directed immune activation can be achieved by local injections of immune modulators in the tumor area or by directing the immune modulator to the tumor using bispecific antibodies. In this review, we focus on therapies targeting checkpoint inhibitors and co-stimulatory receptors that... (More)
The most important goals for the field of immuno-oncology are to improve the response rate and increase the number of tumor indications that respond to immunotherapy, without increasing adverse side effects. One approach to achieve these goals is to use tumor-directed immunotherapy, i.e., to focus the immune activation to the most relevant part of the immune system. This may improve anti-tumor efficacy as well as reduce immune-related adverse events. Tumor-directed immune activation can be achieved by local injections of immune modulators in the tumor area or by directing the immune modulator to the tumor using bispecific antibodies. In this review, we focus on therapies targeting checkpoint inhibitors and co-stimulatory receptors that can generate tumor-specific T cell responses through localized immune activation.
(Less)
- author
- Ellmark, Peter LU ; Mangsbo, Sara M. ; Furebring, Christina LU ; Norlén, Per LU and Tötterman, Thomas H.
- organization
- publishing date
- 2017-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Bispecific antibody, Cancer, Immuno-oncology, Immunotherapy, Intratumoral, Tumor-directed immunotherapy
- in
- Cancer Immunology and Immunotherapy
- volume
- 66
- issue
- 1
- pages
- 7 pages
- publisher
- Springer
- external identifiers
-
- scopus:84990818472
- pmid:27714433
- wos:000393598500001
- ISSN
- 0340-7004
- DOI
- 10.1007/s00262-016-1909-3
- language
- English
- LU publication?
- yes
- id
- 670bdd48-fc94-4de2-98cf-f11fe6fc9190
- date added to LUP
- 2016-11-16 08:18:22
- date last changed
- 2025-01-12 15:13:37
@article{670bdd48-fc94-4de2-98cf-f11fe6fc9190,
abstract = {{<p>The most important goals for the field of immuno-oncology are to improve the response rate and increase the number of tumor indications that respond to immunotherapy, without increasing adverse side effects. One approach to achieve these goals is to use tumor-directed immunotherapy, i.e., to focus the immune activation to the most relevant part of the immune system. This may improve anti-tumor efficacy as well as reduce immune-related adverse events. Tumor-directed immune activation can be achieved by local injections of immune modulators in the tumor area or by directing the immune modulator to the tumor using bispecific antibodies. In this review, we focus on therapies targeting checkpoint inhibitors and co-stimulatory receptors that can generate tumor-specific T cell responses through localized immune activation.</p>}},
author = {{Ellmark, Peter and Mangsbo, Sara M. and Furebring, Christina and Norlén, Per and Tötterman, Thomas H.}},
issn = {{0340-7004}},
keywords = {{Bispecific antibody; Cancer; Immuno-oncology; Immunotherapy; Intratumoral; Tumor-directed immunotherapy}},
language = {{eng}},
number = {{1}},
pages = {{1--7}},
publisher = {{Springer}},
series = {{Cancer Immunology and Immunotherapy}},
title = {{Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation}},
url = {{http://dx.doi.org/10.1007/s00262-016-1909-3}},
doi = {{10.1007/s00262-016-1909-3}},
volume = {{66}},
year = {{2017}},
}